Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
CRESCENT BIOPHARMA, INC. (CBIO)
Standardized SEC financial data for CRESCENT BIOPHARMA, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001253689 · NASDAQ · Pharmaceutical Preparations.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$10.2M
$1.2M
$75K
$10K
—
$10.8M
R&D expense
$44.9M
$47.5M
$28.4M
$20.1M
—
$138.1M
SG&A expense
$16.7M
$17.1M
$19.1M
$19.2M
—
$25.4M
Operating income
-$51.5M
-$63.4M
-$47.4M
-$39.3M
—
-$152.6M
Pretax income
—
—
—
—
—
-$151.9M
Income tax
—
—
—
—
—
$2.0M
Net income
-$51.0M
-$63.4M
-$46.7M
-$36.9M
—
-$153.9M
EPS (diluted)
$-1.12
$-1.23
$-0.89
$-0.58
$-0.59
—
Standardized from CRESCENT BIOPHARMA, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.